MAP2K7 and ovarian serous adenocarcinoma: Our study shows that the use of the oral MEK inhibitor trametinib significantly increased progression-free survival and objective response rate compared with standard-of-care therapies in patients with relapsed or persistent low-grade serous ovarian cancer.